Comparison of predicted and actual adverse event frequencies for gemcitabine treatment.

The predicted (blue markers) and actual proportions (orange markers) of individuals that experience adverse events related to a particular organ or body tissue (represented on the x-axis). The line connecting the marker represents the observed error between the predicted proportion of individuals that would experience adverse events against the actual proportion reported in clinical trials. Each prediction is obtained using a trained model without using the corresponding (held out) observations reported in breast cancer clinical trials that treated patients with gemcitabine. (EPS)